Video
Author(s):
With statins being a common treatment option for high cholesterol and PCSK9 inhibitors gaining traction since their approval in the past year research has looked at just how low a person's LDL, or bad cholesterol can go.
With statins being a common treatment option for high cholesterol and PCSK9 inhibitors gaining traction since their approval in the past year research has looked at just how low a person's LDL, or bad cholesterol can go.
Christopher Cannon, MD, from the Harvard Clinical Research Institute discussed the results of a recent study looking at this topic including one patient whose LDL level was recorded at nearly zero. Cannon presented the results of the study at the 65th Annual Scientific Sessions and Expo of the American College of Cardiology in Chicago.